This report provides details of the latest licensing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date, the report provides details of licensing agreements from 2016 to 2022.
There has been a long standing willingness for parties to enter licensing deals. Such deals enable both parties to benefit from the upside of a big R&D win, whilst mitigating the risks of going it alone in the risky preclinical and clinical development stages.
Licensing is a specific type of partnering deal whereby the parties to the deal agree to commercialize a compound, product or technology.
- Specifically, licensing is the granting of permission to use intellectual property rights, such as trademarks, patents, or technology, under defined conditions
In more recent times, licensing is often the outcome of a successful period of collaboration on the research and development of a technology or compound, resulting in a product which can be commercialized. In this situation, the licensing agreement governs who has permission to commercialize and what payments are due should commercialization proceed.
Other forms of licensing such as sub-licensing and cross-licensing are also explored, with examples provided together with listing of recent deals in pharma, biotech and diagnostics.
The report provides a detailed understand and analysis of how and why companies enter licensing deals. The majority of deals are multicomponent whereby the licensee retains either a right or option to license to commercialize the resultant product of the research collaboration. There are also numerous pure licensing deals whereby the products originator takes on a development/commercialization partner in order to maximize a technologies/products prospects.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of licensing deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in licensing as well as a discussion on the merits of the type of deal.
Chapter 3 provides an overview of the structure of licensing deals. The chapter includes numerous case studies to enable understanding of both pure licensing deals and multicomponent deals where collaborative R&D forms a part.
Chapter 4 provides a review of the leading licensing deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a review of the top 25 most active biopharma companies in licensing. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 6 provides a comprehensive review of licensing financials for deals announced since 2016, including headline value, upfront, milestone payments and royalty rates, providing both benchmark data and access to individual deal financials.
Chapter 7 provides a comprehensive and detailed review of licensing deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.
The report also includes numerous table and figures that illustrate the trends and activities in licensing deal making since 2016.
In addition, a comprehensive appendix is provided organized by licensing company A-Z , stage of development, therapeutic target, technology type and deal type definitions. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about licensing partnering in the research, development and commercialization of technologies and products.
Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2022 provides the reader with the following key benefits:
- In-depth understanding of licensing partnering deal trends since 2016
- Analysis of the structure of licensing agreements with numerous real life case studies
- Comprehensive listing of over 5,000 licensing deals since 2016, together with deal terms, value and press release
- Comprehensive access to actual licensing contracts entered into by the world’s life science companies
- Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates
- Insight into the terms included in a licensing agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scopeGlobal Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016- 2022 is intended to provide the reader with an in-depth understanding of the licensing trends and structure of deals entered into by leading life science companies worldwide.
Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016 - 2022 includes:
- Trends in licensing dealmaking in the biopharma industry since 2016
- Analysis of licensing deal structure
- Case studies of real-life licensing deals
- Comprehensive listing of over 5,000 licensing deals since 2016
- Access to licensing contract documents
- Key financial bnchmarks for headline, upfront, milestone and royalty rates
- The leading licensing deals by value since 2016
- Most active licensing dealmakers since 2016
- The leading licensing partnering resources
In Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2022 available deals and contracts are listed by:
- Company A-Z
- Headline value
- Therapeutic area
- Technology type
The Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2022 report provides comprehensive access to available contract documents for licensing deals.
Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How do milestone align with clinical stage development phases?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Table of Contents
2.2. Definition of licensing deals
2.3. Success factors for licensing deals
2.4. When licensing can be useful
2.5. Attributes of licensing deals
2.6. Trends in licensing deals since 2016
2.6.1. Licensing deal making by year since 2016
2.6.2. Licensing deal making by phase of development since 2016
2.6.3. Licensing deal making by industry sector since 2016
2.6.4. Licensing deal making by therapy area since 2016
2.6.5. Licensing deal making by technology type since 2016
2.6.6. Licensing deal making by most active company since 2016
2.7. Option to license
2.8. Adding co-promotion to the mix
2.9. The future of licensing deals
3.2. Pure versus multi-component licensing deals
3.3. Pure licensing agreement structure
3.3.1. Example licensing agreements
3.3.1.a. Case study 1
3.3.1.b. Case study 2
3.4. Licensing rights as part of a wider alliance agreement
3.4.1. Example licensing clauses
3.4.1.a. Case study 3
3.4.1.b. Case study 4
3.4.2. Example licensing option right clauses
3.4.2.a. Case study 5
3.4.2.b. Case study 6
4.2. Top licensing deals by value
5.2. Top 25 most active licensing dealmakers
6.2. Licensing partnering headline values
6.3. Licensing deal upfront payments
6.4. Licensing deal milestone payments
6.5. Licensing royalty rates
7.2. Licensing deals with contracts since 2016
Appendix 2 - Licensing dealmaking by industry sector
Appendix 3 - Licensing dealmaking by stage of development
Appendix 4 - Licensing dealmaking by therapy area
Appendix 5 - Licensing dealmaking by technology type
Figure 2: Situations where licensing can prove useful
Figure 3: Key attributes of a licensing deal
Figure 4: Trends in licensing deal announcements since 2016
Figure 5: Licensing deals signed at each phase of development since 2016
Figure 6: Licensing deals by industry sector since 2016
Figure 7: Licensing deals by therapy area since 2016
Figure 8: Licensing deals by technology type since 2016
Figure 9: Top 25 most active licensing dealmakers sinnce 2016
Figure 10: Licensing agreements - what should a contract include?
Figure 11: Components of the licensing deal structure
Figure 12: Top licensing deals by value since 2016
Figure 13: Most active licensing dealmakers since 2016
Figure 14: Licensing deals with a headline value
Figure 15: Licensing deals with an upfront value
Figure 16: Licensing deals with a milestone value
Figure 17: Licensing deals with a royalty rate value
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Collaborative R&D
- Contract service
- Equity purchase
- Joint venture
- Royalty financing
- Spin out
- Sub license
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.